Depixus SAS

https://www.depixus.com

LinkedIn: https://www.linkedin.com/company/depixus

Depixus® is a fast-growing innovative biotechnology company based in Paris, France, and Cambridge, UK, developing its cutting-edge MAGNA™ technology to reveal the secrets of the dynamic genome. The technology is set to transform our understanding of how genetics is regulated and provide powerful new insights into the mechanisms of disease. Depixus® is a spin-out from spin-out from Ecole Normale Supérieure (ENS), one of the most prestigious 'grandes écoles' in France. The company has been financed not only through equity investment but also via numerous grants, including from the EU's Horizon 2020 SME Instrument and Innovate UK programmes. The MAGNA™ technology is based on an instrument system called a 'magnetic trap'. Samples of nucleic acid are captured within a flow cell and then can be analysed at multiple levels of resolution. *

	Start	2016-05-06 renamed
	Group	Depixus (Group)
	Predecessor	PicoSeq
	Industry	genomic technology
	Industry 2	MAGNA™ technology (Depixus)
	Person	Hamilton, Gordon (Depixus 202112 CEO + Co-Founder)
	Person 2	Berriman, John (Abingworth)

	Region	Paris
	Country	France
	Street	3–5 impasse Reille
	City	75014 Paris
	Tel	+33-9-7248-2089
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Depixus SAS. (12/15/21). "Press Release: Depixus Raises EUR 30.6M (USD 35.4M) in Series A Financing". Paris & Cambridge.

		Record changed: 2024-03-30